Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Dec;60(12):1081–1085. doi: 10.1136/ard.60.12.1081

Behçet's disease and thrombophilia

M Leiba 1, Y Sidi 1, H Gur 1, A Leiba 1, M Ehrenfeld 1
PMCID: PMC1753444  PMID: 11709446

Full Text

The Full Text of this article is available as a PDF (110.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitchison R., Chu P., Cater D. R., Harris R. J., Powell R. J. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis. 1989 Jul;48(7):590–593. doi: 10.1136/ard.48.7.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akar N., Misirlioğlu M., Akar E., Avcu F., Yalçin A., Sözüz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol. 1998 Jul;58(3):249–249. doi: 10.1002/(sici)1096-8652(199807)58:3<249::aid-ajh20>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  3. Alarcón-Segovia D., Cabral A. R. The concept and classification of antiphospholipid/cofactor syndromes. Lupus. 1996 Oct;5(5):364–367. doi: 10.1177/096120339600500505. [DOI] [PubMed] [Google Scholar]
  4. Altinbaş A., Aytemur K., Tokgözoğlu L., Oztürk M., Koşar A., Haznedaroğlu I. C., Kirazli S., Dündar S. V. Hyperhomocysteinaemia and activated protein C resistance in Behçet's disease. J Intern Med. 2000 Sep;248(3):267–268. doi: 10.1046/j.1365-2796.2000.00711.x. [DOI] [PubMed] [Google Scholar]
  5. Arbesfeld S. J., Kurban A. K. Behçet's disease. New perspectives on an enigmatic syndrome. J Am Acad Dermatol. 1988 Nov;19(5 Pt 1):767–779. [PubMed] [Google Scholar]
  6. Barger A. P., Hurley R. Evaluation of the hypercoagulable state. Whom to screen, how to test and treat. Postgrad Med. 2000 Sep 15;108(4):59–17. doi: 10.3810/pgm.2000.09.15.1236. [DOI] [PubMed] [Google Scholar]
  7. Bergman R., Lorber M., Lerner M., Brik R., Friedman-Birnbaum R. Anticardiolipin antibodies in Behçet's disease. J Dermatol. 1990 Mar;17(3):164–167. doi: 10.1111/j.1346-8138.1990.tb01619.x. [DOI] [PubMed] [Google Scholar]
  8. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  9. Bertina R. M. The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol. 1998 Sep;5(5):339–342. doi: 10.1097/00062752-199809000-00006. [DOI] [PubMed] [Google Scholar]
  10. Demirer S., Sengül N., Yerdel M. A., Tüzüner A., Ulus A. T., Gürler A., Bergqvist D., Siegbahn A., Karacagil S. Haemostasis in patients with Behçet's disease. Eur J Vasc Endovasc Surg. 2000 Jun;19(6):570–574. doi: 10.1053/ejvs.2000.1091. [DOI] [PubMed] [Google Scholar]
  11. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991 Feb 5;266(4):2459–2465. [PubMed] [Google Scholar]
  12. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999 Apr 17;353(9161):1348–1353. doi: 10.1016/S0140-6736(98)10362-8. [DOI] [PubMed] [Google Scholar]
  13. Gül A., Aslantas A. B., Tekinay T., Koniçe M., Ozçelik T. Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology (Oxford) 1999 Dec;38(12):1298–1299. doi: 10.1093/rheumatology/38.12.1298. [DOI] [PubMed] [Google Scholar]
  14. Gül A., Ozbek U., Oztürk C., Inanç M., Koniçe M., Ozçelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease. Br J Rheumatol. 1996 Nov;35(11):1178–1180. doi: 10.1093/rheumatology/35.11.1178. [DOI] [PubMed] [Google Scholar]
  15. Gürgey A., Gurler A., Oner A. F., Mesci L., Kirazli S. Thrombomodulin levels in Behçet's disease with and without the factor V Leiden mutation. Clin Rheumatol. 1998;17(3):186–188. doi: 10.1007/BF01451044. [DOI] [PubMed] [Google Scholar]
  16. Gürgey A., Hicsönmez G., Parlak H., Balta G., Celiker A. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol. 1998 Oct;59(2):179–180. doi: 10.1002/(sici)1096-8652(199810)59:2<179::aid-ajh16>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  17. Hampton K. K., Chamberlain M. A., Menon D. K., Davies J. A. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost. 1991 Sep 2;66(3):292–294. [PubMed] [Google Scholar]
  18. Haznedaroglu I. C., Ozcebe O. I., Ozdemir O., Celik I., Dündar S. V., Kirazli S. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Intern Med. 1996 Oct;240(4):181–187. doi: 10.1046/j.1365-2796.1996.396853000.x. [DOI] [PubMed] [Google Scholar]
  19. Haznedaroğlu I. C., Ozcebe O., Celik I., Dündar S. V., Kirazhi S. Haemostatic markers of procoagulant imbalance in Behçet's disease. Eur J Haematol. 1996 Jul;57(1):107–108. doi: 10.1111/j.1600-0609.1996.tb00499.x. [DOI] [PubMed] [Google Scholar]
  20. Haznedaroğlu I. C., Ozdemir O., Ozcebe O., Dündar S. V., Kirazli S. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease. Thromb Haemost. 1996 Jun;75(6):974–975. [PubMed] [Google Scholar]
  21. Haznedaroğlu S., Karaaslan Y., Haznedaroğlu I. C., Dündar S. V. Behçet's disease as a prethrombotic state. Int J Clin Lab Res. 1998;28(3):200–200. doi: 10.1007/BF02874109. [DOI] [PubMed] [Google Scholar]
  22. Hull R. G., Harris E. N., Gharavi A. E., Tincani A., Asherson R. A., Valesini G., Denman A. M., Froude G., Hughes G. R. Anticardiolipin antibodies: occurrence in Behçet's syndrome. Ann Rheum Dis. 1984 Oct;43(5):746–748. doi: 10.1136/ard.43.5.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hursting M. J., Stead A. G., Crout F. V., Horvath B. Z., Moore B. M. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem. 1993 Apr;39(4):683–686. [PubMed] [Google Scholar]
  24. Koç Y., Güllü I., Akpek G., Akpolat T., Kansu E., Kiraz S., Batman F., Kansu T., Balkanci F., Akkaya S. Vascular involvement in Behçet's disease. J Rheumatol. 1992 Mar;19(3):402–410. [PubMed] [Google Scholar]
  25. Koşar A., Haznedaroğlu I. C., Büyükaşik Y., Kirazli S., Dündar S. V. Activated protein C resistance in Behçet's disease. Rheumatol Int. 1998;17(6):249–250. doi: 10.1007/s002960050043. [DOI] [PubMed] [Google Scholar]
  26. Kuzu M. A., Ozaslan C., Köksoy C., Gürler A., Tüzüner A. Vascular involvement in Behçet's disease: 8-year audit. World J Surg. 1994 Nov-Dec;18(6):948–954. doi: 10.1007/BF00299119. [DOI] [PubMed] [Google Scholar]
  27. Lê Thi Huong D., Wechsler B., Papo T., Piette J. C., Bletry O., Vitoux J. M., Kieffer E., Godeau P. Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol. 1995 Nov;22(11):2103–2113. [PubMed] [Google Scholar]
  28. Mader R., Ziv M., Adawi M., Mader R., Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. J Rheumatol. 1999 Nov;26(11):2404–2408. [PubMed] [Google Scholar]
  29. Mammo L., Al-Dalaan A., Bahabri S. S., Saour J. N. Association of factor V Leiden with Behçet's disease. J Rheumatol. 1997 Nov;24(11):2196–2198. [PubMed] [Google Scholar]
  30. Mohri M., Sata M., Gomi K., Maruyama Y., Osame M., Maruyama I. Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin. Lupus. 1997;6(7):590–596. doi: 10.1177/096120339700600706. [DOI] [PubMed] [Google Scholar]
  31. Mutlu S., Scully C. The person behind the eponym: Hulûsi Behçet (1889-1948). J Oral Pathol Med. 1994 Aug;23(7):289–290. doi: 10.1111/j.1600-0714.1994.tb00063.x. [DOI] [PubMed] [Google Scholar]
  32. Nalçaci M., Pekçelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behçet's disease. J Int Med Res. 1998 Aug-Sep;26(4):206–208. doi: 10.1177/030006059802600405. [DOI] [PubMed] [Google Scholar]
  33. Oner A. F., Gürgey A., Gürler A., Mesci L. Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol. 1998 Mar;25(3):496–498. [PubMed] [Google Scholar]
  34. Orem A., Değer O., Memiş O., Bahadir S., Ovali E., Cimşit G. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease. Ann Rheum Dis. 1995 Sep;54(9):726–729. doi: 10.1136/ard.54.9.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ozdemir Y., Onder F., Yarangümeli A., Kükkuyumcu C., Kural G. Anticardiolipin antibodies and retinal vascular complications in Behçet's disease. Ophthalmic Surg Lasers. 1997 Aug;28(8):653–656. [PubMed] [Google Scholar]
  36. Pelzer H., Schwarz A., Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988 Feb 25;59(1):101–106. [PubMed] [Google Scholar]
  37. Pivetti-Pezzi P., Priori R., Catarinelli G., Meroni P. L., Federici A. B., Abdulaziz M., Falco M., Valesini G. Markers of vascular injury in Behçet's disease associated with retinal vasculitis. Ann Ophthalmol. 1992 Nov;24(11):411–414. [PubMed] [Google Scholar]
  38. Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R. M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996 Nov 15;88(10):3698–3703. [PubMed] [Google Scholar]
  39. Priori R., Conti F., Pittoni V., Garofalo T., Sorice M., Valesini G. Is there a role for anti-phospholipid-binding protein antibodies in the pathogenesis of thrombosis in Behcet's disease? Thromb Haemost. 2000 Jan;83(1):173–174. [PubMed] [Google Scholar]
  40. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med. 1999 Oct 21;341(17):1284–1291. doi: 10.1056/NEJM199910213411707. [DOI] [PubMed] [Google Scholar]
  41. Sengül N., Demirer S., Yerdel M. A., Terzioğlu G., Akin B., Gürler A., Tüzüner A. Comparison of coagulation parameters for healthy subjects and Behçet disease patients with and without vascular involvement. World J Surg. 2000 Dec;24(12):1584–1588. doi: 10.1007/s002680010282. [DOI] [PubMed] [Google Scholar]
  42. Sorice M., Pittoni V., Circella A., Misasi R., Conti F., Longo A., Pontieri G. M., Valesini G. Anti-prothrombin but not "pure" anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost. 1998 Oct;80(4):713–715. [PubMed] [Google Scholar]
  43. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  44. Tokay S., Direskeneli H., Yurdakul S., Akoglu T. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford) 2001 Feb;40(2):192–195. doi: 10.1093/rheumatology/40.2.192. [DOI] [PubMed] [Google Scholar]
  45. Toydemir P. B., Elhan A. H., Tükün A., Toydemir R., Gürler A., Tüzüner A., Bökesoy I. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. J Rheumatol. 2000 Dec;27(12):2849–2854. [PubMed] [Google Scholar]
  46. Tunaci A., Berkmen Y. M., Gökmen E. Thoracic involvement in Behçet's disease: pathologic, clinical, and imaging features. AJR Am J Roentgenol. 1995 Jan;164(1):51–56. doi: 10.2214/ajr.164.1.7998568. [DOI] [PubMed] [Google Scholar]
  47. Verity D. H., Vaughan R. W., Madanat W., Kondeatis E., Zureikat H., Fayyad F., Kanawati C. A., Ayesh I., Stanford M. R., Wallace G. R. Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol. 1999 Sep;128(3):352–356. doi: 10.1016/s0002-9394(99)00184-1. [DOI] [PubMed] [Google Scholar]
  48. Wilson A. P., Efthimiou J., Betteridge D. J. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest. 1988 Aug;18(4):410–414. doi: 10.1111/j.1365-2362.1988.tb01032.x. [DOI] [PubMed] [Google Scholar]
  49. Yamana K., Kosuga K., Kinoshita H., Uraguchi K., Kinoshita T., Hirata Y., Akashi H., Nakayama T., Ohishi K. Vasculo-Behçet's disease: immunological study of the formation of aneurysm. J Cardiovasc Surg (Torino) 1988 Nov-Dec;29(6):751–755. [PubMed] [Google Scholar]
  50. Yazici H., Barnes C. G. Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs. 1991 Nov;42(5):796–804. doi: 10.2165/00003495-199142050-00006. [DOI] [PubMed] [Google Scholar]
  51. Yazici H., Hekim N., Ozbakir F., Yurdakul S., Tüzün Y., Pazarli H., Müftüoğlu A. Von Willebrand factor in Behçet's syndrome. J Rheumatol. 1987 Apr;14(2):305–306. [PubMed] [Google Scholar]
  52. Zouboulis C. C., Büttner P., Tebbe B., Orfanos C. E. Anticardiolipin antibodies in Adamantiades-Behçet's disease. Br J Dermatol. 1993 Mar;128(3):281–284. doi: 10.1111/j.1365-2133.1993.tb00172.x. [DOI] [PubMed] [Google Scholar]
  53. al-Dalaan A. N., al Balaa S. R., el Ramahi K., al-Kawi Z., Bohlega S., Bahabri S., al Janadi M. A. Behçet's disease in Saudi Arabia. J Rheumatol. 1994 Apr;21(4):658–661. [PubMed] [Google Scholar]
  54. al-Dalaan A. N., al-Ballaa S. R., al-Janadi M. A., Bohlega S., Bahabri S. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçets disease. Clin Rheumatol. 1993 Mar;12(1):28–30. doi: 10.1007/BF02231554. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES